

**ANNEX I**  
**SUMMARY OF PRODUCT CHARACTERISTICS**

## 1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Porcilis PCV ID emulsion for injection for pigs

## 2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Each dose of 0.2 ml contains:

### Active substance:

Porcine circovirus type 2 ORF2 subunit antigen  $\geq 1436 \text{ AU}^1$

### Adjuvants:

dl- $\alpha$ -tocopheryl acetate 0.6 mg

Light liquid paraffin 8.3 mg

<sup>1</sup> Antigenic units as determined in the *in vitro* potency test (antigenic mass assay).

### Excipients:

Qualitative composition of excipients and other constituents
Polysorbate 80
Simethicone
Sodium chloride
Potassium chloride
Disodium phosphate dihydrate
Potassium dihydrogen phosphate
Water for injections

Homogenous, white to nearly white emulsion after shaking.

## 3. CLINICAL INFORMATION

### 3.1 Target species

Pigs.

### 3.2 Indications for use for each target species

For the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by PCV2 infection. To reduce loss of daily weight gain and mortality associated with PCV2 infection.

Onset of immunity: 2 weeks after vaccination.

Duration of immunity: 26 weeks after vaccination.

### 3.3 Contraindications

None.

### 3.4 Special warnings

Vaccinate healthy animals only.

### 3.5 Special precautions for use

#### Special precautions for safe use in the target species:

Use of the vaccine in boars has not been evaluated.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals:

To the user:

This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

#### Special precautions for the protection of the environment:

Not applicable.

### 3.6 Adverse events

Pigs:

Very common (>1 animal / 10 animals treated):	Injection site swelling*
--	--------------------------

\* mostly consisting of hard non-painful swellings of up to 2 cm diameter. A biphasic pattern of the injection site swelling, consisting of an increase and decrease followed by another increase and decrease of the size, is commonly observed. In individual pigs the size may increase to 6.5 cm and redness and/or scabs may be observed. The injection site swellings disappear completely within approximately 7 weeks after vaccination

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder or its local representative or the national competent authority via the national reporting system. See also the last section of the package leaflet for respective contact details.

### 3.7 Use during pregnancy, lactation or lay

Can be used during pregnancy and lactation.

### 3.8 Interaction with other medicinal products and other forms of interaction

Safety and efficacy data are available in pigs from 3 weeks of age onwards which demonstrate that this vaccine can be administered mixed with Porcilis Lawsonia ID (see section 3.9 below) and/or non-mixed with Porcilis M Hyo ID ONCE and/or non-mixed with Porcilis PRRS (intradermal route). The administration site of non-mixed vaccines should be separated by at least 3 cm. The product literature of Porcilis Lawsonia ID, Porcilis M Hyo ID ONCE and Porcilis PRRS should be consulted before administration.

Adverse events are as described in section 3.6, except for injection site swelling where a maximum size of up to 7 cm may occur in individual pigs. Injection site swelling may last up to 7 weeks and are very commonly accompanied by redness and crusts. If the crust is rubbed off, some small skin damage may be commonly observed. Elevated temperature on the day of vaccination (mean 0.3 °C, in

individual pigs up to 2°C) is common. The animal's temperature returns to normal within 1-2 days after the peak temperature is observed. Lying down and malaise can be uncommonly observed in vaccinated pigs.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except for the products mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

### 3.9 Administration routes and dosage

For intradermal use.

Before using the vaccine allow it to reach room temperature (15°C – 25°C) and shake well before use. Avoid multiple broaching.

Intradermal administration of 0.2 ml per animal, preferably at the sides of the neck, along the muscles of the back or in the hind leg (all pigs) or perianal area (in pigs for reproduction) using a multi-dose needle-free injection device for intradermal application of liquids suitable to deliver a “jet-stream” volume of vaccine (0.2 ml ± 10 %) through the epidermal layers of the skin.

Safety and efficacy of Porcilis PCV ID have been demonstrated using the device IDAL.

#### Vaccination scheme:

Vaccinate once from an age of 3 weeks onwards and re-vaccination at 26 weeks interval is recommended.

#### *Mixed use with Porcilis Lawsonia ID*

Porcilis PCV ID may be used to reconstitute Porcilis Lawsonia ID lyophilisate shortly before vaccination in pigs from 3 weeks of age onwards as follows:

Porcilis Lawsonia ID lyophilisate	Porcilis PCV ID
50 doses	10 ml
100 doses	20 ml

For proper reconstitution and correct administration, use the following procedure:

1. Allow Porcilis PCV ID to reach room temperature and shake well before use.
2. Add approximately 5-10 ml of Porcilis PCV ID to the Porcilis Lawsonia ID lyophilisate and mix briefly.
3. Withdraw the reconstituted concentrate from the vial and transfer it back into the vial with the Porcilis PCV ID. Shake briefly to mix.
4. Use the vaccine suspension within 6 hours of reconstitution. Any vaccine remaining at the end of this time should be discarded.

#### Dosage:

A single dose (0.2 ml) of Porcilis Lawsonia ID mixed with Porcilis PCV ID is given intradermally in the neck.

Visual appearance after reconstitution: homogenous white to nearly white emulsion after shaking.

Avoid introduction of a contamination by multiple broaching.

### 3.10 Symptoms of overdose (and where applicable, emergency procedures and antidotes)

No data available.

### **3.11 Special restrictions for use and special conditions for use, including restrictions on the use of antimicrobial and antiparasitic veterinary medicinal products in order to limit the risk of development of resistance**

Not applicable.

### **3.12 Withdrawal periods**

Zero days.

## **4. IMMUNOLOGICAL INFORMATION**

### **4.1 ATCvet code: QI09AA07**

The product stimulates the development of active immunity against porcine circovirus type 2 in pigs.

## **5. PHARMACEUTICAL PARTICULARS**

### **5.1 Major incompatibilities**

Do not mix with any other veterinary medicinal product except those mentioned in section 3.8.

### **5.2 Shelf life**

Shelf-life of the veterinary medicinal product as packaged for sale: 2 years.

Shelf-life after first opening the immediate packaging: 8 hours.

### **5.3 Special precautions for storage**

Store in a refrigerator (2 °C – 8 °C).

Do not freeze.

Protect from direct sunlight.

### **5.4 Nature and composition of immediate packaging**

Glass vial (type I) of 10 ml closed with a nitril-based rubber stopper and sealed with an aluminium cap.

PET (polyethylene terephthalate) vial of 20 ml closed with a nitril-based rubber stopper and sealed with an aluminium cap.

Pack size:

Cardboard box with 1 glass vial of 10 ml.

Cardboard box with 10 glass vials of 10 ml.

Cardboard box with 1 PET vial of 20 ml.

Cardboard box with 10 PET vials of 20 ml.

Not all pack sizes may be marketed.

### **5.5 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any national collection systems applicable to the veterinary medicinal product concerned.

**6. NAME OF THE MARKETING AUTHORISATION HOLDER**

Intervet International B.V.

**7. MARKETING AUTHORISATION NUMBER(S)**

EU/2/15/187/001

EU/2/15/187/002

EU/2/15/187/003

EU/2/15/187/004

**8. DATE OF FIRST AUTHORISATION**

Date of first authorisation: 28/08/2015.

**9. DATE OF THE LAST REVISION OF SUMMARY OF THE PRODUCT CHARACTERISTICS**

{MM/YYYY}

**10. CLASSIFICATION OF VETERINARY MEDICINAL PRODUCTS**

Veterinary medicinal product subject to prescription.

Detailed information on this veterinary medicinal product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

## **ANNEX II**

### **OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION**

None

**ANNEX III**  
**LABELLING AND PACKAGE LEAFLET**



## **A. LABELLING**

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE**

CARDBOARD BOX

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Porcilis PCV ID emulsion for injection for pigs

**2. STATEMENT OF ACTIVE SUBSTANCES**

Per 0.2 ml:  
PCV2 ORF2 subunit antigen  $\geq$  1436 AU

**3. PACKAGE SIZE**

10 ml  
20 ml  
10 x 10 ml  
10 x 20 ml

**4. TARGET SPECIES**

Pigs

**5. INDICATIONS**

**6. ROUTES OF ADMINISTRATION**

Intradermal use.

**7. WITHDRAWAL PERIODS**

Withdrawal period: zero days.

**8. EXPIRY DATE**

Exp. {mm/yyyy} Once broached use within 8 hours.

**9. SPECIAL STORAGE PRECAUTIONS**

Store in a refrigerator.  
Do not freeze  
Protect from direct sunlight.

**10. THE WORDS "READ THE PACKAGE LEAFLET BEFORE USE"**

Read the package leaflet before use.

**11. THE WORDS “FOR ANIMAL TREATMENT ONLY”**

For animal treatment only.

**12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”**

Keep out of the sight and reach of children.

**13. NAME OF THE MARKETING AUTHORISATION HOLDER**

Intervet International B.V.

**14. MARKETING AUTHORISATION NUMBERS**

EU/2/15/187/001 (1x 10ml)  
EU/2/15/187/002 (10x 10ml)  
EU/2/15/187/003 (1x 20ml)  
EU/2/15/187/004 (10x 20ml)

**15. BATCH NUMBER**

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS**

VIALS OF 10 AND 20 ML

**1. NAME OF THE VETERINARY MEDICINAL PRODUCT**

Porcilis PCV ID



**2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES**

PCV2 ORF2 subunit antigen

10 ml

20 ml

**3. BATCH NUMBER**

Lot {number}

**4. EXPIRY DATE**

Exp. {mm/yyyy}

**B. PACKAGE LEAFLET**

## PACKAGE LEAFLET:

### 1. Name of the veterinary medicinal product

Porcilis PCV ID emulsion for injection for pigs

### 2. Composition

Each dose of 0.2 ml contains:

#### Active substance:

Porcine circovirus type 2 ORF2 subunit antigen  $\geq 1436 \text{ AU}^1$

#### Adjuvants:

dl- $\alpha$ -tocopheryl acetate 0.6 mg

Light liquid paraffin 8.3 mg

<sup>1</sup>Antigenic units as determined in the *in vitro* antigenic mass assay.

Emulsion for injection.

Homogenous, white to nearly white emulsion after shaking.

### 3. Target species

Pigs.

### 4. Indications for use

For the active immunisation of pigs to reduce viraemia, virus load in lungs and lymphoid tissues and virus shedding caused by PCV2 infection. To reduce loss of daily weight gain and mortality associated with PCV2 infection.

Onset of immunity: 2 weeks after vaccination.

Duration of immunity: 26 weeks after vaccination.

### 5. Contraindications

None.

### 6. Special warnings

#### Special warnings:

Vaccinate healthy animals only.

#### Special precautions for safe use in the target species:

Use of the vaccine in boars has not been evaluated.

#### Special precautions to be taken by the person administering the veterinary medicinal product to animals

To the user:

This veterinary medicinal product contains mineral oil. Accidental injection/self-injection may result in severe pain and swelling, particularly if injected into a joint or finger, and in rare cases could result in the loss of the affected finger if prompt medical attention is not given. If you are accidentally injected with this veterinary medicinal product, seek prompt medical advice even if only a very small amount is injected and take the package leaflet with you. If pain persists for more than 12 hours after medical examination, seek medical advice again.

To the physician:

This veterinary medicinal product contains mineral oil. Even if small amounts have been injected, accidental injection with this product can cause intense swelling, which may, for example, result in ischaemic necrosis and even the loss of a digit. Expert, PROMPT, surgical attention is required and may necessitate early incision and irrigation of the injected area, especially where there is involvement of finger pulp or tendon.

Special precautions for the protection of the environment:

Not applicable.

Pregnancy and lactation:

Can be used during pregnancy and lactation.

Interaction with other medicinal products and other forms of interaction

Safety and efficacy data are available in pigs from 3 weeks of age onwards which demonstrate that this vaccine can be administered mixed with Porcilis Lawsonia ID (see section 8 below) and/or non-mixed with Porcilis M Hyo ID ONCE and/or non-mixed with Porcilis PRRS (intradermal route). The administration site of non-mixed vaccines should be separated by at least 3 cm. The product literature of Porcilis Lawsonia ID, Porcilis M Hyo ID ONCE and Porcilis PRRS should be consulted before administration.

Adverse events are as described in section 7, except for injection site swelling where a maximum size of up to 7 cm may occur in individual pigs. Injection site swelling may last up to 7 weeks and are very commonly accompanied by redness and crusts. If the crust is rubbed off, some small skin damage may be commonly observed. Elevated temperature on the day of vaccination (mean 0.3 °C, in individual pigs up to 2°C) is common. The animal's temperature returns to normal within 1-2 days after the peak temperature is observed. Lying down and malaise can be uncommonly observed in vaccinated pigs.

No information is available on the safety and efficacy of this vaccine when used with any other veterinary medicinal product except the product mentioned above. A decision to use this vaccine before or after any other veterinary medicinal product therefore needs to be made on a case by case basis.

Major incompatibilities

Do not mix with any other veterinary medicinal product except those mentioned above.

**7. Adverse events**

Pigs:

Very common (>1 animal / 10 animals treated):	Injection site swelling*
--	--------------------------

\* mostly consisting of hard non-painful swellings of up to 2 cm diameter. A biphasic pattern of the injection site swelling, consisting of an increase and decrease followed by another increase and decrease of the size, is commonly observed. In individual pigs the size may increase to 6.5 cm and redness and/or scabs may be observed. The injection site swellings disappear completely within approximately 7 weeks after vaccination

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice any side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report

any adverse events to the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system.

## **8. Dosage for each species, routes and method of administration**

For intradermal use.

Intradermal administration of 0.2 ml per animal, preferably at the sides of the neck, along the muscles of the back or in the hind leg (all pigs) or perianal area (in pigs for reproduction) using a multi-dose needle-free injection device for intradermal application of liquids suitable to deliver a “jet-stream” volume of vaccine (0.2ml ± 10%) through the epidermal layers of the skin.

Safety and efficacy of Porcilis PCV ID have been demonstrated using the device IDAL.

### Vaccination scheme:

Vaccinate once from an age of 3 weeks onwards and re-vaccination at 26 weeks interval is recommended.

### *Mixed use with Porcilis Lawsonia ID*

Porcilis PCV ID may be used to reconstitute Porcilis Lawsonia ID lyophilisate shortly before vaccination in pigs from 3 weeks of age onwards as follows:

Porcilis Lawsonia ID lyophilisate	Porcilis PCV ID
50 doses	10 ml
100 doses	20 ml

For proper reconstitution and correct administration, use the following procedure:

1. Allow Porcilis PCV ID to reach room temperature and shake well before use.
2. Add approximately 5-10 ml of Porcilis PCV ID to the Porcilis Lawsonia ID lyophilisate and mix briefly.
3. Withdraw the reconstituted concentrate from the vial and transfer it back into the vial with the Porcilis PCV ID. Shake briefly to mix.
4. Use the vaccine suspension within 6 hours of reconstitution. Any vaccine remaining at the end of this time should be discarded.

### Dosage:

A single dose (0.2 ml) of Porcilis Lawsonia ID mixed with Porcilis PCV ID is given intradermally in the neck.

Visual appearance after reconstitution: homogenous white to nearly white emulsion after shaking.

Avoid introduction of a contamination by multiple broaching.

## **9. Advise on correct administration**

Before using the vaccine allow it to reach room temperature (15 °C – 25 °C) and shake well before use.

Avoid multiple broaching.

## **10. Withdrawal periods**

Zero days.

## **11. Special storage precautions**



Keep out of the sight and reach of children.

Store in a refrigerator (2 °C - 8 °C).

Do not freeze.

Protect from direct sunlight.

Do not use this veterinary medicinal product after the expiry date which is stated on the label after Exp.

Shelf life after first opening the immediate packaging: 8 hours.

## **12. Special precautions for disposal**

Medicines should not be disposed of via wastewater or household waste.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist on how to dispose of medicines no longer required.

## **13. Classification of veterinary medicinal products**

Veterinary medicinal product subject to prescription.

## **14. Marketing authorisation numbers and pack sizes**

EU/2/15/187/001-004.

Cardboard box with 1 or 10 vials of 10 or 20 ml.

Not all pack sizes may be marketed.

## **15. Date on which the package leaflet was last revised**

{MM/YYYY}

Detailed information on this product is available in the Union Product Database (<https://medicines.health.europa.eu/veterinary>).

## **16. Contact details**

Marketing authorisation holder and manufacturer responsible for batch release:

Intervet International B.V.

Wim de Körverstraat 35

5831 AN Boxmeer

The Netherlands

Contact details to report suspected adverse reactions:

### **België/Belgique/Belgien**

MSD Animal Health Belgium BV-SRL

Tél/Tel: + 32 (0)2 370 94 01

### **Lietuva**

Intervet International B.V.

Tel: + 37052196111

**Република България**  
Intervet International B.V.  
Тел: + 359 28193749

**Česká republika**  
Intervet s.r.o.  
Tel: + 420 233 010 242

**Danmark**  
MSD Animal Health A/S  
Tlf: + 45 44 82 42 00

**Deutschland**  
Intervet Deutschland GmbH  
Tel: + 49 (0)8945614100

**Eesti**  
Intervet International B.V.  
Tel: + 37052196111

**Ελλάδα**  
Intervet Hellas A.E.  
Τηλ: + 30 210 989 7452

**España**  
Merck Sharp & Dohme Animal Health S.L.  
Tel: + 34 923 19 03 45

**France**  
Intervet S.A.S / Intervet / MSD Santé Animale  
Tél: + 33 (0)241228383

**Hrvatska**  
Intervet International B.V. podružnica u  
Republici Hrvatskoj  
Tel: + 385 1 6611339

**Ireland**  
Intervet (Ireland) Limited  
Tel: + 353 (0) 1 2970220

**Ísland**  
Vistor hf.  
Sími: + 354 535 7000

**Italia**  
MSD Animal Health S.r.l.  
Tel: + 39 02 516861

**Κύπρος**  
Intervet Hellas A.E.  
Τηλ: + 30 210 989 7452

**Luxembourg/Luxemburg**  
MSD Animal Health Belgium BV-SRL  
Tél/Tel: + 32 (0)2 370 94 01

**Magyarország**  
Intervet Hungaria Kft./ Intervet Hungaria  
Értékesítő Kft.  
Tel.: + 36 1 439 4597

**Malta**  
Intervet International B.V.  
Tel: + 39 02 516861

**Nederland**  
MSD Animal Health-Intervet Nederland B.V.  
Tel: + 32 (0)2 370 94 01

**Norge**  
MSD Animal Health Norge AS  
Tlf: + 47 55 54 37 35

**Österreich**  
Intervet Ges.mb.H.  
Tel: + 43 (1) 256 87 87

**Polska**  
Intervet Sp. z o.o.  
Tel.: + 48 22 18 32 200

**Portugal**  
MSD Animal Health Lda.  
Tel: + 351 214 465 700

**România**  
Intervet Romania S.R.L.  
Tel: + 40 21 311 83 11

**Slovenija**  
Intervet International B.V.  
Podružnica u Republici Hrvatskoj  
Tel: + 385 1 6611339

**Slovenská republika**  
Intervet s.r.o.  
Tel: + 420 233 010 242

**Suomi/Finland**  
MSD Animal Health Oy  
Puh/Tel: + 358 10 2310 750

**Sverige**  
MSD Animal Health Sweden AB  
Tel: + 46 (0)8 522 216 60

**Latvija**  
Intervet International B.V.  
Tel: + 37052196111

**United Kingdom (Northern Ireland)**  
Intervet (Ireland) Limited  
Tel: + 353 (0) 1 2970220

**17. Other information**